Drug Trial Radar · NCT00404924
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
Last checked: Nov 20, 2026Latest source record: Sep 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,140
Actual
Start
Nov 2006
Primary completion
Oct 2009
Study completion Nov 2014
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 29, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred after previous chemotherapy and an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). ZD6474 is a new anti-cancer drug in development that works in a different way to standard chemotherapy drugs. It targets the growth of new blood vessels to a tumour and thereby might slow the rate at which the tumour may grow. Early studies indicate that ZD6474 has a positive effect on the time that a tumour may take to progress to a further stage. Approximately 930 patients will take part in this study. It will be conducted in hospitals and clinics in North and South America, Europe and Asia.
Conditions
- Non-Small-Cell Lung Carcinoma
Interventions
ZD6474 (vandetanib)Drug
once daily oral tablet
Best Supportive CareOther
standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Time to death in months
Locations
102 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona
Research Site
Germantown, Tennessee
Research Site
Bahía Blanca, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
La Plata, Argentina
Research Site
Rosario, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
Santa Fe, Argentina
Research Site
Fitzroy, Australia
Research Site
Perth, Australia
Research Site
St Leonards, Australia
Research Site
Tugan, Australia
Research Site
Woodville South, Australia
Research Site
Linz, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Antwerp, Belgium
Research Site
Brussels (Woluwé-St-Lambert), Belgium
Research Site
Charleroi, Belgium
Research Site
Edegem, Belgium
Research Site
Ghent, Belgium
Research Site
Leuven, Belgium
Research Site
Liège, Belgium
Research Site
Edmonton, Alberta, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, China
Research Site
Chengdu, China
Research Site
Dalian, China
Research Site
Guangzhou, China
Research Site
Nanjing, China
Research Site
Shanghai, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Brest, France
Research Site
Caen, France
Research Site
Lyon, France
Research Site
Marseille, France
Research Site
Nice, France
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.